Evidence map›Paper›PMID 34108651›Full record

ReviewActa pharmacologica Sinica2022

Role of TRPM2 in brain tumours and potential as a drug target.

Delphine Ji, Zheng-Wei Luo, Andrea Ovcjak, Rahmah Alanazi, Mei-Hua Bao, Zhong-Ping Feng, Hong-Shuo Sun

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmacologica Sinica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Delphine JiDepartment of Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Zheng-Wei LuoDepartment of Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Andrea OvcjakDepartment of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Rahmah AlanaziDepartment of Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Mei-Hua BaoScience Research Center, Changsha Medical University, Changsha, 410219, China.
Zhong-Ping FengDepartment of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. zp.feng@utoronto.ca.
Hong-Shuo SunDepartment of Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. hss.sun@utoronto.ca.
University of Toronto · CAChangsha Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ion channels are ubiquitously expressed in almost all living cells, and are the third-largest category of drug targets, following enzymes and receptors. The transient receptor potential melastatin (TRPM) subfamily of ion channels are important to cell function and survival. Studies have shown upregulation of the TRPM family of ion channels in various brain tumours. Gliomas are the most prevalent form of primary malignant brain tumours with no effective treatment; thus, drug development is eagerly needed. TRPM2 is an essential ion channel for cell function and has important roles in oxidative stress and inflammation. In response to oxidative stress, ADP-ribose (ADPR) is produced, and in turn activates TRPM2 by binding to the NUDT9-H domain on the C-terminal. TRPM2 has been implicated in various cancers and is significantly upregulated in brain tumours. This article reviews the current understanding of TRPM2 in the context of brain tumours and overviews the effects of potential drug therapies targeting TRPM2 including hydrogen peroxide (H

Indexed as

Brain NeoplasmsTRPM Cation ChannelsAdenosine Diphosphate RiboseCalciumHumansHydrogen PeroxideOxidative StressAdenosine Diphosphate RiboseCalciumHydrogen PeroxideTRPM2 protein, humanTRPM Cation Channelsdrug developmentdrug targetgliomasion channelsTRPM2

Identifiers

PMID34108651
PMCPMC8975829
OpenAlexW3166899797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.